Roche Holding Ltd

Roche Holding Ltd

472.49
USD
-11.35
(-2.35%)
333.97BMarket Cap
Jan 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
54.51
55.24
55.91
58.66
61.74
65.78
70.96
67.41
73.01
81.29
74.75
77.36
78.65
- -
Basic EPS, GAAP
13.01
10.86
10.29
11.11
10
12.15
15.58
16.52
16.19
15.34
14.22
10.26
15.99
- -
Free Cash Flow per Basic Share
15.05
14.66
12.94
11.43
16
17.42
20.19
13.73
19.1
16.37
14.16
18.7
16.23
- -
Dividend per Share
7.41
7.82
8.07
8.17
8.27
8.39
8.6
8.9
9.04
9.2
9.39
9.48
9.6
- -
Book Value per Share
22.46
22.78
24.33
27.73
30.6
31.97
37.81
42.09
30.23
34.61
36.34
39.47
41.98
40.55
Tangible Book Value per Share
9.55
-3.66
-4.6
0.68
9.25
10.8
13.51
17.46
1.93
9.26
6.32
8.18
8.68
6.95
Basic Weighted Avg Shares
858
859
861
862
863
864
866
865
860
810
809
807
806
796
Sales/Revenue/Turnover
46,780
47,462
48,145
50,576
53,299
56,846
61,466
58,323
62,801
65,814
60,441
62,395
63,356
- -
Operating Margin (%)
35.01
29.69
28.71
27.82
24.4
25.98
28.55
31.79
28.91
26.55
25.47
21.5
29.16
- -
Depreciation Expense
2,381
2,623
3,640
3,941
3,887
3,586
4,292
4,558
4,443
3,844
3,464
3,423
3,386
- -
Net Income, GAAP
11,164
9,332
8,863
9,576
8,633
10,500
13,497
14,295
13,930
12,421
11,498
8,277
12,880
- -
Effective Tax Rate (%)
22.51
23.81
24.45
25.17
27.95
23.2
15.08
16.13
14.16
17.13
12.22
22.1
18.7
- -
Profit Margin (%)
23.86
19.66
18.41
18.93
16.2
18.47
21.96
24.51
22.18
18.87
19.02
13.27
20.33
- -
Working Capital
13,404
8,006
4,414
6,070
9,412
9,211
7,135
7,541
-2,789
6,577
8,622
13,013
10,728
6,590
LT Debt
16,423
19,347
17,100
16,992
15,839
16,077
13,547
11,096
17,101
22,282
26,092
32,097
28,674
25,222
Total Equity
21,241
21,558
23,300
26,402
29,007
30,366
35,867
39,773
28,345
32,015
33,263
36,161
37,880
36,716
Return on Invested Capital (%)
29.84
23.5
21.12
20.95
18.26
21.79
27.59
27.28
25.4
23.07
21.1
14.73
20.08
- -
Return on Capital (%)
29.52
23.01
20.28
21.27
18.59
22.09
26.96
26.23
22.89
19.89
18.78
12.39
18.18
- -
Return on Common Equity (%)
66.04
48
43.7
42.66
34.29
38.84
44.72
41.38
45.8
47.34
40.13
27.1
39.29
- -

Capital Structure

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
ST Debt
6,567
4,517
6,583
LT Borrowings
26,464
27,430
25,222
LT Finance Leases
- -
1,244
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
806
805
806
Market Capitalization
207,320
263,431
269,789

Working Capital

CHF

•

in mil. unless spec.
Jun'25
Dec'25
Jun'26
Total Current Assets
35,702
38,729
35,437
Cash, Cash Equivalents & STI
12,026
15,476
9,734
Accounts Receivable, Net
11,918
12,391
12,915
Inventories
7,597
7,479
8,094
Total Current Liabilities
27,580
28,001
28,847
Payables & Accruals
- -
- -
- -
ST Debt
6,567
4,517
6,583
Deferred Revenue
- -
- -
- -

Growth Rates

CHF

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.85%
0.32%
4.75%
Free Cash Flow
4.55%
4.76%
-13.34%
Net Income, GAAP
6.11%
1.36%
55.61%
Sales/Revenue/Turnover
2.92%
1.82%
1.54%
Total Cash Common Dividend
1.08%
0.1%
1.06%

Semi-annual Revenue

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
62,395
2025
- -
- -
63,356
2026
- -
- -
- -

Semi-annual Earnings Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
10.26
2025
- -
- -
15.99
2026
- -
- -
- -

Semi-annual Dividends Per Share

CHF

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
9.48
2025
- -
- -
9.6
2026
- -
- -
- -

Company Description

CEO
Thomas Schinecker
Full Time Employees
112,774
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Grenzacherstrasse 124 Basel BS Switzerland 4070
IPO Date
May 4, 2001
Website
roche.com
Business
Roche Holding AG is a Swiss multinational healthcare company that develops, manufactures and markets pharmaceuticals and diagnostics worldwide. Founded in 1896 and headquartered in Basel, Switzerland, the company operates through two primary segments: Pharmaceuticals, which focuses on prescription medicines in oncology, immunology, infectious diseases, neuroscience, ophthalmology, haematology, inflammatory and respiratory diseases, cardiovascular and metabolic disorders; and Diagnostics, which provides in vitro diagnostic equipment, reagents and solutions including professional diagnostics, molecular diagnostics, diabetes care, tissue diagnostics and applied science products targeting physicians, hospitals, clinics, consumers and research settings in academia and industry. Roche maintains a global presence with significant operations across Europe, North America, Asia-Pacific and other regions, and holds majority ownership in Chugai Pharmaceutical in Japan while fully owning Genentech in the United States. In recent developments, Roche entered a definitive merger agreement in September 2025 to acquire 89bio for up to $3.5 billion to bolster its cardiovascular, renal and metabolic diseases portfolio with pegozafermin, a phase 3 FGF21 analog for moderate to severe metabolic dysfunction-associated steatohepatitis (MASH); received European Commission conditional approval for subcutaneous Lunsumio in relapsed/refractory follicular lymphoma; reported positive phase III results for fenebrutinib in multiple sclerosis; and announced a clinical trial collaboration with KaliVir Immunotherapeutics for oncology immunotherapies, alongside prior acquisitions such as Carmot Therapeutics in 2024, Televant Holdings and Good Therapeutics programs.

Company News

  • RHHBY Secures FDA Approval for Breast Cancer Treatment

  • Roche Secures First U.S. Approval for New Breast-Cancer Pill

  • FDA Approves Genentech's WILSERDLY (Giredestrant), a Next-Generation Oral SERD, for ER-Positive, ESR1-Mutated Advanced Breast Cancer

  • FDA approves Roche's Wilserdly (giredestrant), a next-generation oral SERD, for ER-positive, ESR1-mutated advanced breast cancer

  • US FDA approves Roche's oral treatment for advanced breast cancer

  • Roche receives FDA De Novo authorization for cobas® pro i 601 platform with Ionify® Gabapentin assay, advancing automated mass spectrometry for routine clinical laboratories

  • Chances of Jensen Huang returning to Nvidia 'very slim': David Roche

  • Faeth Therapeutics Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate PIKTOR in Combination with a Selective Estrogen Receptor Degrader in HR+/HER2- Advanced Breast Cancer

  • Perficient Expands Its Innovation Center to Advance Roche Diagnostics' Molecular Laboratory Systems

  • Roche receives FDA 510(k) clearance for new cobas® eplex respiratory pathogen panel 3, enabling labs to customize respiratory testing for local patient needs

  • Roche: Valuation Leaves Limited Upside

  • Brown Advisory Flexible Equity Strategy: Q3 2026 Top Contributors And Detractors

  • Roche strengthens cancer diagnostic portfolio with launch of test for differential diagnosis of mesothelioma

  • Roche receives CE Mark for cobas® smart e immunoanalyser, completing a portfolio that brings central-lab precision to healthcare settings ranging from small clinics to large hospital laboratories

  • Billions in New Plants, Trillions in Potential Obesity-Drug Revenue Over Two Decades

  • Breakfast News: Science Strikes Back at Cancer

  • Roche Targets Emerging Oncology Market With New Lung-Cancer Drug

  • Roche says divarasib cut risk of death 44% in lung cancer trial

  • Roche's divarasib demonstrated best-in-class efficacy, advancing the standard of care in previously treated KRAS G12C-mutated lung cancer

  • Genentech's Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer